Immunoma (NASDAQ: IMNM) Downgraded by Zacks Investment Research to “Sell”


Immunoma (NASDAQ: IMNM) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report released Thursday, Zacks.com reports.

According to Zacks, “Immunome, Inc. is a biopharmaceutical company using a proprietary human memory B cell platform to discover and develop first-class therapeutic antibodies designed to change the way diseases are currently treated. Immunome, Inc. is based in Exton, United States. “

Separately, Cantor Fitzgerald began covering the actions of Immunoma in a research note on Friday, October 29. They issued an “overweight” rating and a target price of $ 35.00 on the stock.

IMNM opened at $ 14.42 on Thursday. The company has a market cap of $ 174.48 million, a price-to-earnings ratio of -7.67 and a beta of -4.11. Immunoma has a one year minimum of $ 9.27 and a one year maximum of $ 63.78. The company has a 50-day moving average price of $ 17.87 and a two-hundred-day moving average price of $ 17.60.

Immunoma (NASDAQ: IMNM) last released its quarterly results on Monday, November 15. The company reported ($ 0.65) earnings per share (EPS) for the quarter, missing Zacks’ consensus estimate of ($ 0.51) from ($ 0.14). As a group, research analysts expect Immunome to post earnings per share of -2.1 for the current fiscal year.

A number of institutional investors have recently changed their positions in IMNM. Vanguard Group Inc. increased its stake in Immunome by 95.9% in the 2nd quarter. Vanguard Group Inc. now owns 302,092 shares of the company valued at $ 5,226,000 after purchasing an additional 147,863 shares in the last quarter. Alpine Global Management LLC increased its stake in Immunome by 7.4% during the 2nd quarter. Alpine Global Management LLC now owns 854,671 shares of the company valued at $ 14,786,000 after purchasing an additional 58,962 shares in the last quarter. Millennium Management LLC purchased a new stake in Immunome during the second quarter for a value of approximately $ 634,000. Royal Bank of Canada increased its holdings in Immunome by 8,271.1% in the second quarter. Royal Bank of Canada now owns 28,127 shares of the company valued at $ 487,000 after purchasing an additional 27,791 shares last quarter. Finally, Renaissance Technologies LLC purchased a new position in Immunome shares during the second quarter valued at approximately $ 353,000. Institutional investors and hedge funds hold 24.86% of the company’s shares.

(A d)

Access our leading research platform which includes MarketBeat Daily Premium, portfolio monitoring tools, stock filters, research tools, real-time news feed, email and SMS alerts , the MarketBeat idea engine, exclusive brokerage rankings, extensive data export tools and more. Save 50% on your 2022 subscription. Only $ 1.00 for the first 30 days.

Immunome Company Profile

Immunome, Inc., a biopharmaceutical company, discovers and develops therapeutic antibodies for oncology and infectious diseases. The company’s main oncology program includes IMM-ONC-01, which targets the tumor-derived immune checkpoint IL-38 capable of promoting immune system evasion. She is also developing IMM-BCP-01, a candidate antibody cocktail for the treatment of SARS-CoV-2 and COVID-19 infections.

Featured article: Economic reports

Get a Free Copy of Zacks’ Immunome Research Report (IMNM)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in Immunome now?

Before you consider Immunome, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the top five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold … and Immunome was not on the list.

While Immunome currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here

Previous The town and village of Massena organize special meetings to finalize the transfer of the rescue team | Health issues
Next Romania's economic outlook: Ease of resilience is key anchor in 2022 as reformist government collapses